Clinical Trials Directory

Trials / Completed

CompletedNCT01121640

A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women

A Randomized Controlled Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
854 (actual)
Sponsor
Fred Hutchinson Cancer Center · Academic / Other
Sex
Female
Age
25 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The Novel Markers Trial will compare the safety, feasibility and effectiveness of two different epithelial ovarian cancer screening strategies that use CA125 and add HE4 as either a first or second line screen. This study is the next step in a larger research effort to develop a blood test that can be used as a screening method for the early detection of epithelial ovarian cancer.

Detailed description

Epithelial ovarian cancer (EOC) is usually lethal unless it is diagnosed at an early stage, thus early detection is likely to play an important role in reducing its mortality. Within the Ovarian Specialized Programs of Research Excellence Pacific Ovarian Cancer Research Consortium (POCRC) researchers have been working for a decade to discover, develop, and validate biomarkers (proteins or substances found in blood) that could help save lives by detecting EOC early. During the last five years several biomarkers, including CA125, have been evaluated for their ability to detect EOC at an earlier stage. The best markers will now be studied in a new randomized controlled trial of ovarian cancer screening.

Conditions

Interventions

TypeNameDescription
PROCEDURECA125 assay on Abbott Architect i1000SR platformBead-based sandwich ELISA style assay
PROCEDUREHE4 assay on Architect i1000SR platformBead-based sandwich ELISA style assay
PROCEDURETransvaginal UltrasoundSonogram will be obtained only if confirmatory markers are elevated. Exam is restricted to ovarian evaluation.

Timeline

Start date
2009-11-01
Primary completion
2015-05-07
Completion
2015-05-07
First posted
2010-05-12
Last updated
2018-12-13

Locations

5 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01121640. Inclusion in this directory is not an endorsement.